PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1681335
PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1681335
The global capsule endoscopy market is valued at approximately USD 411.31 million in 2023 and is expected to grow at a healthy CAGR of 7.9% over the forecast period 2024-2032. Capsule endoscopy is an advanced, non-invasive diagnostic technology that utilizes a swallowable, wireless capsule equipped with a miniature camera to capture high-resolution images of the gastrointestinal (GI) tract. The increasing prevalence of gastrointestinal diseases, colorectal cancer, and Crohn's disease, coupled with the growing demand for minimally invasive diagnostic procedures, is propelling the adoption of capsule endoscopy worldwide.
The market is further driven by the introduction of technologically advanced capsule endoscopes, such as magnetically controlled capsules, AI-powered diagnostic tools, and improved battery-operated devices with enhanced imaging capabilities. The integration of artificial intelligence in capsule endoscopy systems has significantly improved the accuracy of detecting lesions and abnormalities, thereby reducing diagnostic errors and enhancing patient outcomes. Additionally, the rising awareness about early disease detection and increasing patient preference for painless and efficient diagnostic methods are contributing to market expansion.
Supportive reimbursement policies and the increasing adoption of capsule endoscopy in hospitals and outpatient facilities are also fueling market growth. Many healthcare institutions are actively investing in advanced endoscopic technologies to improve their diagnostic capabilities. For instance, in January 2025, CapsoVision received U.S. FDA clearance for its CapsoCam Plus, a wireless capsule endoscopy device approved for use in pediatric patients aged two and above. Such regulatory approvals and innovations are creating lucrative growth opportunities for market players.
The small bowel capsule endoscopy segment dominates the market due to its extensive use in diagnosing obscure gastrointestinal bleeding (OGIB), Crohn's disease, and small intestine tumors. The colon capsule endoscopy segment is projected to grow at the fastest rate during the forecast period, driven by the rising emphasis on colorectal cancer screening and increasing government initiatives to promote early cancer detection. Moreover, the growing aging population, which is more prone to gastrointestinal disorders, is expected to boost demand for capsule endoscopy procedures.
Regionally, North America leads the global capsule endoscopy market, accounting for a significant revenue share in 2024. The region's dominance is attributed to the high prevalence of GI disorders, advanced healthcare infrastructure, and strong presence of key market players. In the U.S., the demand for capsule endoscopy is driven by an increasing preference for minimally invasive diagnostic solutions, alongside favorable insurance reimbursement policies. Meanwhile, the Asia Pacific region is anticipated to witness the fastest growth rate, with China, Japan, and India emerging as key markets. The expansion of healthcare facilities, rising investments in medical technology, and growing patient awareness about non-invasive endoscopy are key factors supporting the growth of capsule endoscopy in this region.